TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 194524
Drug: Antibiotic-corticosteroid suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-corticosteroid suspension
Study: 25954025
Drug: Violet syrup
Normalized name: acid violet 43
Approvals — FDA: no, EMA: no, PMDA: no
Description: Violet syrup
Study: 21425885
Drug: Oral indomethacin/prochlorperazine/caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral indomethacin/prochlorperazine/caffeine
Study: 21425885
Drug: Rectal indomethacin/prochlorperazine/caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal indomethacin/prochlorperazine/caffeine
Study: 17490753
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) group intervention
Study: 1460211
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (IB) nasal spray (84 micrograms/nostril, two sprays per nostril, four times a day for 4 days)
Study: 1460211
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (IB) nasal spray
Study: 6419709
Drug: XYY men
Approvals — FDA: no, EMA: no, PMDA: no
Description: XYY men with higher concentrations of testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH)
Study: 31158087
Drug: Docetaxel (75mg/m2)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (75mg/m2) administered alongside standard of care (SOC) hormone therapy for ≥2 years and radiotherapy in some patients.
Study: 31158087
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) hormone therapy for ≥2 years and radiotherapy in some patients.
Study: 22658231
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic (group L)
Study: 15852407
Drug: Once-daily radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily radiotherapy (QDRT)
Study: 15852407
Drug: Twice-daily radiotherapy
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily radiotherapy (BIDRT)
Study: 12774967
Drug: Aspirin 25
Normalized name: aspirin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 25 mg/kg PO q8h
Study: 8420491
Drug: Oral azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azathioprine (100 to 150 mg/d) in combination with oral prednisolone (1 mg/kg per day)
Study: 8420491
Drug: Four large-volume
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four large-volume plasma exchanges in combination with oral prednisolone (1 mg/kg per day)
Study: 8420491
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (1 mg/kg per day) alone
Study: 3541816
Drug: Milacemide 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milacemide 400 mg b.i.d. (week 1)
Study: 3541816
Drug: Milacemide 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milacemide 1,200 mg b.i.d. (week 2)
Study: 3541816
Drug: Milacemide 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milacemide 400 mg (superimposed dosage on day 8)
Study: 3541816
Drug: Milacemide 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milacemide 1,200 mg (superimposed dosage on day 15)
Study: 3541816
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment (1 week and 2 weeks)
Study: 22731754
Drug: 500/100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500/100 μg fluticasone/salmeterol Diskus daily
Study: 22731754
Drug: 400/24 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/24 μg extrafine beclomethasone/formoterol pMDI daily
Study: 20092966
Drug: modafinil (400mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: modafinil (400mg once daily)
Study: 20092966
Drug: placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (once daily)
Study: 18682624
Drug: Phentolamine mesylate
Normalized name: Phentolamine Mesylate
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phentolamine mesylate (PM) injection
Study: 18682624
Drug: Control (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (sham injection)
Study: 16425390
Drug: Cefotaxime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (1 g every 6 h for 5 days)
Study: 16425390
Drug: Amikacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin (500 mg once daily for 5 days)
Study: 10389550
Drug: Beclomethasone 168
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone 168 micrograms plus salmeterol 42 micrograms twice daily
Study: 10389550
Drug: Beclomethasone 336
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone 336 micrograms twice daily
Study: 1354949
Drug: Mizolastine (SL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine (SL 85.0324) 2 mg to 75 mg
Study: 1354949
Drug: Mizolastine (SL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine (SL 85.0324) 10 mg
Study: 1354949
Drug: Mizolastine (SL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine (SL 85.0324) up to 75 mg
Study: 6373217
Drug: Naftidrofuryl (Dusodril)
Normalized name: naftidrofuryl
DrugBank: Naftidrofuryl (DB13588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (Dusodril) 600 mg orally
Study: 28069480
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (400 μg)
Study: 28069480
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (400 μg)
Study: 24856464
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no cervical priming agent)
Study: 24856464
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (oral, sublingual, vaginal)
Study: 20832986
Drug: Buspirone (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (a serotonin-selective agonist) administered in a double-blind, randomized, placebo-controlled protocol.
Study: 11039606
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate (MPSL: 10 mg/kg body weight)
Study: 11039606
Drug: MPSL followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MPSL followed by continuous infusion of urinary trypsin inhibitor (UTI) for 3 days
Study: 11039606
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of MPSL
Study: 11039606
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of UTI in early postoperative phase after MPSL
Study: 11039606
Drug: Preoperative MPSL
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative MPSL followed by UTI infusion for only one hour
Study: 2218733
Drug: Dinoprostone (Prepidil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone (Prepidil Gel) applied 6 hours before abortion
Study: 2218733
Drug: Dinoprostone (Prepidil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone (Prepidil Gel) applied 4 hours before abortion
Study: 2218733
Drug: Dinoprostone (Prepidil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone (Prepidil Gel)
Study: 340949
Drug: Single 3-g
Normalized name: glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 3-g oral dose of amoxicillin
Study: 340949
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (10 days of amoxicillin, 250 mg, four times per day)
Study: 28864219
Drug: Regenerative endodontic
Normalized name: Regener-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regenerative endodontic treatment (RET)
Study: 23503480
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg/day) for 12 months
Study: 17014579
Drug: Phlebotomy therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlebotomy therapy (removal of 300-500 mL of blood every 14 days until serum ferritin < 100 microg/L)
Study: 17014579
Drug: Control (follow-up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (follow-up without phlebotomy therapy)
Study: 2008865
Drug: Naltrexone (100-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (100-150 mg/d)
Study: 6807439
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone 600 mg/m2 daily for three days
Study: 6807439
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 3 mg/kg daily for three days
Study: 30608050
Drug: Vaccine-plus-behavior-change (handwashing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-plus-behavior-change (handwashing promotion and drinking water chlorination)
Study: 30608050
Drug: Cholera-vaccine-only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholera-vaccine-only
Study: 26886418
Drug: Pioglitazone (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (target dose, 45 mg daily)
Study: 22148897
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate (1 or 2 g/day)
Study: 17947609
Drug: AA/DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA/DHA supplementation (10 gel caps containing 500 mg of AA and 1000 mg of DHA daily for 6 weeks)
Study: 17947609
Drug: OA/LA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: OA/LA supplementation (250 mg of linolenic acid and 125 mg of oleic acid daily for 6 weeks)
Study: 15617993
Drug: Cisplatin (CP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CP) + Vinorelbine (VNR) 25 mg/m(2) on days 1 and 8 as an intravenous bolus plus CP 75 mg/m(2) on day 1 (regimen A)
Study: 15617993
Drug: Cisplatin (CP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CP) + Gemcitabine (GEM) 1200 mg/m(2) on days 1 and 8 as an intravenous 30-min infusion plus CP 75 mg/m(2) on day 1 (regimen B)
Study: 7798688
Drug: PRP polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP polysaccharide vaccine
Study: 7798688
Drug: Hib conjugate
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hib conjugate PRP-D vaccine
Study: 7798688
Drug: Hib conjugate
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hib conjugate HbOC vaccine
Study: 7798688
Drug: No vaccine
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: No vaccine (unimmunized)
Study: 7798688
Drug: Conjugate vaccines
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugate vaccines
Study: 7798688
Drug: PRP conjugate
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP conjugate vaccines
Study: 30396622
Drug: Yoga as
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga as an adjunct therapy
Study: 27550184
Drug: Gongjin-dan (GJD)
Normalized name: PANAX GINSENG FRUIT 229 mg in 4 g ORAL PELLET [Korea Gongjin-Dan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gongjin-dan (GJD) administered twice daily
Study: 24508316
Drug: Manual mobilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual mobilization of the wrist (10 minutes, integrated into therapy twice a week for 6 weeks)
Study: 24508316
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (therapy based on Dutch guidelines for stroke without manual mobilization)
Study: 17170051
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg BIIL 284
Study: 17170051
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg BIIL 284
Study: 17170051
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg BIIL 284
Study: 9794948
Drug: Early surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early surfactant treatment (100 mg/kg body weight bovine surfactant)
Study: 9794948
Drug: Late surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late surfactant treatment (100 mg/kg body weight bovine surfactant)
Study: 9794948
Drug: Early surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early surfactant treatment
Study: 2615932
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of L-tryptophan
Study: 208034
Drug: Quinestrol 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinestrol 0.2 mg once weekly
Study: 208034
Drug: Quinestrol 0.1
Normalized name: quinestrol 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinestrol 0.1 mg once weekly
Study: 208034
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens 1.25 mg daily for 21 days on and 7 days off
Study: 30601336
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of tenofovir (TDF) and telbivudine (LdT)
Study: 30601336
Drug: Tenofovir (TDF)
Normalized name: emtricitabine/tenofovir (TDF) 200 mg-300 mg ORAL TABLET
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir (TDF) single treatment
Study: 27364375
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium dialysate (1.3 mmol/L)
Study: 27364375
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium dialysate (1.6 or 1.75 mmol/L)
Study: 17689755
Drug: Lavender aromatherapy
Normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lavender aromatherapy (four drops of essential oil diluted with 20 ml of hot water and inhaled for 30 min)
Study: 12497304
Drug: Fluoxetin (37
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetin (37 patients, dosage: 20-40 mg/day)
Study: 12497304
Drug: Amitriptyline (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (40 patients, dosage: 25-75 mg/day)
Study: 7540898
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (200 micrograms)
Study: 7540898
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (800 micrograms)
Study: 7540898
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (400 micrograms)
Study: 1673953
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg daily (n = 54)
Study: 1673953
Drug: H2 receptor
Normalized name: Histamine H2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 receptor antagonist (n = 53)
Study: 6269769
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus prophylactic whole brain radiation therapy
Study: 24247554
Drug: GM‐CSF (leukine),
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF (leukine), 500 μg/day 3 times a week for 4 weeks
Study: 11069440
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (once daily for 9 days)
Study: 11069440
Drug: Intravenous amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amlodipine
Study: 1591054
Drug: Formestane 250
Normalized name: formestane 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formestane 250 mg
Study: 1591054
Drug: Formestane 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formestane 500 mg
Study: 8507221
Drug: Leucovorin (2.5-5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin (2.5-5.0 mg orally, given 24 hours after weekly methotrexate dose)
Study: 8507221
Drug: Placebo (given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (given 24 hours after weekly methotrexate dose)
Study: 28843819
Drug: Rifampicin-based systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin-based systemic antibiotics (oral rifampicin with clindamycin or trimethoprim/sulfamethoxazole for 7 days plus nasal mupirocin)
Study: 28843819
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with mupirocin only
Study: 25494594
Drug: Corn peptides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn peptides (CPs) 4 g/d for 9 weeks
Study: 25494594
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (2 g twice daily)
Study: 25494594
Drug: Corn starch
Normalized name: Corn Starch
DrugBank: Starch, corn (DB11599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn starch placebo (2 g twice daily)
Study: 22430300
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection (50 U BT into the internal sphincter)
Study: 20362857
Drug: Custom PRK
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Custom PRK (wavefront-guided custom treatment)
Study: 15714983
Drug: Combined androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined androgen blockade using LHRH agonist and androgen antagonist
Study: 15714983
Drug: Adjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormonal therapy (including intermittent hormonal therapy)
Study: 12879653
Drug: Metformin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin with gonadotropins
Study: 11051123
Drug: Sulthiame (STM)
Normalized name: Sulthiame
DrugBank: Sulthiame (DB08329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulthiame (STM) 5 mg/kg/day
Study: 9006790
Drug: Peppermint oil
Normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppermint oil (90 mg) and caraway oil (50 mg) in an enteric coated capsule
Study: 1587072
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg extended-release fenfluramine plus 15 mg phentermine resin
Study: 3890395
Drug: Muzolimine (MZ)
Normalized name: Muzolimine
DrugBank: Muzolimine (DB13801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muzolimine (MZ) 20 mg/day
Study: 3890395
Drug: Chlorthalidone (CL)
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (CL) 50 mg/day
Study: 29419569
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg every day
Study: 26689970
Drug: No detectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: No detectable drug
Study: 23321657
Drug: Daily vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vaginal estrogen cream for 2 to 12 weeks
Study: 21406117
Drug: Continuous ultrasound
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ultrasound plus exercise therapy
Study: 21406117
Drug: Placebo ultrasound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ultrasound plus exercise therapy
Study: 20081257
Drug: Preoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative intravenous tramadol (100 mg)
Study: 17915641
Drug: Nimesulide in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide in tablets
Study: 3122600
Drug: Naloxone infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone infusion (0.4 mg loading dose followed by 10 micrograms.kg‐1.hr‐1)
Study: 3122600
Drug: Naloxone infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone infusion (0.2 mg loading dose followed by 5 micrograms.kg‐1.hr‐1)
Study: 3122600
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (20 ml/hr)
Study: 29307459
Drug: Non-ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ICD therapy
Study: 28006855
Drug: Lenalidomide and
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide and low-dose dexamethasone (Rd)
Study: 26223257
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg + ASA 100 mg
Study: 26223257
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg + ASA 100 mg
Study: 21173036
Drug: Heparin-coated CPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated CPB (HC-group)
Study: 12135019
Drug: Omeprazole with
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole with or without additional antibiotic therapy
Study: 8620666
Drug: Zileuton 600mg
Normalized name: ZILEUTON 600MG TAB
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zileuton 600mg 4 times daily
Study: 31944870
Drug: Accurate productions
Normalized name: Accutane Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accurate productions of real words (e.g., 'leaf')
Study: 31944870
Drug: Misarticulated words
Normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misarticulated words (e.g., 'weaf' or 'yeaf')
Study: 27710808
Drug: High-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity statin therapy (atorvastatin 80 mg or rosuvastatin 40 mg daily)
Study: 19535099
Drug: Myofascial physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial physical therapy
Study: 20085491
Drug: Raltegravir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir (400 mg twice daily) plus optimized background therapy